Iron Deficiency Anemia Therapy Market Size & Share, by Age Group (Adults, Pediatric, Geriatric); Product Type; Therapy Areas; Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

North America Market Analysis

North America iron deficiency anemia therapy market is anticipated to capture revenue share of over 42.9% by 2037. The region’s proprietorship is backed by its strong emphasis on healthcare accessibility and wide distribution channels. The adequate infrastructure allows local professionals to offer every sufferer an accurate diagnosis and prompt response. In addition, the presence of global generics pioneers has accumulated a wide range of supplements, enabling consumers with affordable selections. According to a report from the Association of Accessible Medicines (AAM), the generic and biosimilar drugs industry saved around USD 445.0 billion for habitants and healthcare systems in the U.S. in 2023.

The extensive insurance coverage and proactive government initiatives are boosting the U.S. iron deficiency anemia therapy market. Additionally, the biologics excellence of this country is also escalating the frequency of clinical discoveries in this field, widening its reach. Furthermore, the combined effort from both public and private authorities to spread awareness about the preventions and curatives of IDA has propelled participation from local producers. For instance, in July 2021, Sandoz commenced immediate commercialization of its solely developed intravenous iron, Ferumoxytol Injection in this country. This strategic expansion was intended to occupy a steady position in the global IV iron industry, worth more than USD 1.0 billion.   

Canada is propagating the iron deficiency anemia therapy market with its increased involvement in biopharmaceutical R&D. The government-issued favorable policies and grants are continuously fueling this landscape by enabling a strong local drug discovery network. Moreover, the enlarging scope for biologics and biosimilars is subsequently fostering a promising future for global leaders, encouraging them to enlist this country in their marketing strategy. For instance, in August 2024, Kye Pharmaceuticals gained market authorization from Canada regulatory ACCRUFeR (ferric maltol). This prescription-only oral medicine is capable of reducing ID and IDA widespread in adults across the nation.

APAC Market Statistics

The iron deficiency anemia therapy market in Asia Pacific is predicted to showcase the fastest growth over the assessed period. The rising cases of anemia in this region, particularly in low- and middle-income countries, are evidence of the presence of a larger marketplace. According to the IHME database, South Asia was reported to have a 35.7% prevalence of erythrocytopenia in 2021. Foreign investments to improve the medical infrastructure in these countries are also ensuring the exponential growth of this regional territory. For instance, in November 2022, The Foundation for the National Institutes of Health allocated USD 6.0 million to escalate R&D in IV iron methods. This fund was dedicated to post-pregnancy IDA in seven low- and middle-income nations including Bangladesh, India, and Pakistan.

India is augmenting the regional iron deficiency anemia therapy market with an inflating demand for affordable and accessible regimens. The absence of established infrastructure and the rising patient population are conjugately garnering lucrative opportunities for investment in this category. In addition, the collaborative effort from government and private organizations such as Anaemia Mukt Bharat (AMB) strategy (launched in 2018) to spread awareness throughout the country. For instance, in May 2022, Emcure Pharmaceuticals launched the EmWocal campaign in association with the Federation of Obstetrics and Gynaecologists of India (FOGSI).

China is also paving its way towards global leadership in the iron deficiency anemia therapy market with higher prevalence and strong manufacturing capabilities. It is steadily leveraging its speed of drug development in various medical categories by conducting meticulous clinical and preclinical studies. Such a progressive and adaptive atmosphere of this country is further attracting both domestic and international pioneers to participate. For instance, in November 2022, CSL Vifor opted for Fresenius Kabi Co. Ltd. to manufacture and market its intravenous iron therapy, Ferinject, after getting approval from the National Medical Products Administration (NMPA) in China.